Intrathecal Cytarabine, Methotrexate, and Hydrocortisone for the Prevention of High-Grade Chimeric Antigen Receptor T-Cell-Associated Neurotoxicity Syndrome

Summary

This phase II trial tests how well cytarabine (Ara-C), methotrexate, and hydrocortisone given between the spinal cord and the membranes that protect it (intrathecal \[IT\]) works in preventing high-grade immune effector-associated neurotoxicity syndrome (ICANS) in patients receiving chimeric antigen receptor (CAR) T-cell therapy. ICANS is a challenging complication of CAR T-cell therapy that causes neurological effects varying from mild headaches or temporary confusion to hallucinations, swelling in the brain, and seizures. Between 20%-70% of patients receiving CAR T-cell therapy show symptoms of neurotoxicity.

Eligibility

Inclusion Criteria:

* Written informed consent. Participant or legally authorized representative (LAR) must provide written informed consent prior to any study-specific procedures or interventions
* Age ≥ 18 years. All genders, races, and ethnic groups will be included
* Must be receiving SOC Yescarta® or Tecartus® in the inpatient setting
* Agree to adhere to institutional guidelines for contraception during the first 30 days post CAR-T

  * Rationale for eligibility criteria based on contraception and pregnancy (both participants and partners of a sperm-producing participant): It shall be known to all participants that the effects of CAR-T or IT chemotherapy on the developing human fetus are unknown. For this reason, persons of reproductive potential must agree to use adequate contraception. Should a participant or participant's sexual partner become pregnant or suspect a pregnancy while participating in this study, the individual should inform their treating physician immediately
* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
* Platelet count \> 50,000/mm\^3 (μL)
* Adequate coagulation tests including international normalized ratio (INR) \< 1.6 and fibrinogen \> 100

Exclusion Criteria:

* Active/concurrent diagnosis of any central nervous system (CNS) hematologic malignancy

  * History or presence of CNS disorder such as poorly controlled seizure disorder (seizure within the 12 months), transverse myelitis, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, or any autoimmune disease with CNS involvement
* Known history of hypersensitivity to IT chemotherapy
* Subject has a contraindication to LP including:

  * Presence of a posterior fossa mass
  * Skin infection near puncture site
  * Uncorrected bleeding diathesis
  * Suspicion of increased intracranial pressure
  * Acute spinal cord trauma
* Subject is receiving an antiplatelet and/or anticoagulant that cannot be held prior to LP according to best available evidence
* Known bleeding disorders
* Any other significant medical illness, abnormality, or condition that would, in the Investigator's judgement, make the participant inappropriate for study participation or would put the participant at risk

Conditions2

Interventions3

Locations1 site

Find trials near these locations

Related trials

• A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS. — Ascentage Pharma Group Inc.
• Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil — Instituto do Cancer do Estado de São Paulo
• Blinatumomab Plus Venetoclax Sequenced With Inotuzumab Ozogamicin in Treating B-ALL — First Affiliated Hospital of Zhejiang University
• Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML — Children's Hospital of Soochow University
• Comparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma Patients — The Affiliated People's Hospital of Ningbo University
• Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma — The Affiliated People's Hospital of Ningbo University
• Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia Patients — Institute of Hematology & Blood Diseases Hospital, China
• Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL — Institute of Hematology & Blood Diseases Hospital, China

Browse More Trials